Innovative Nutraceutical Effectively Manages Canine Atopy

Abstract

Like people, dogs may be allergic to numerous substances that their bodies touch or are found in the air or in food. These allergens enter the body by inhalation, direct contact or absorption, i.e., through the skin or respiratory or gastrointestinal tracts. Recognized as foreign entities, the canine response is the release of inflammatory cells and the regulation of histamine levels as defence mechanisms. Innumerable prescription and over-the-counter treatments have been advanced in attempts to relieve the clinical signs associated with canine seasonal allergies. The primary aim of this multisite, prospective open label trial was to support anecdotal postmarketing surveillance reports that the non-prescription canine chew under study provided significant benefits for the treatment of canine allergic dermatitis. A secondary aim was to elicit responses from groomers and pet parents who used the product for their dogs. Animals presented at random with lesions consistent with a diagnosis of allergic dermatitis were enrolled during the normal course of business at the veterinary hospital and groomers’ shops. Pet parents, groomers and veterinarians reported that a twice-a-day treatment regimen resulted in the reduction or alleviation of one or more cardinal signs of canine allergic dermatitis in 83.3% of the enrolled dogs. These findings warrant the use of Dermabliss Seasonal Allergy Chews alone or in conjunction with other treatments) for dogs with allergic dermatitis.